Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]
Awaiting development
Reference number: GID-TA11281
Expected publication date: TBC
Following on from advice received from the company, timelines for this appraisal are to be confirmed.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.